Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19


      The Centers for Disease Control and Prevention advises that patients with moderate to severe asthma belong to a high-risk group that is susceptible to severe coronavirus disease 2019 (COVID-19). However, the association between asthma and COVID-19 has not been well-established.


      The primary objective was to determine the prevalence of asthma among patients with COVID-19 in a major US health system. We assessed the clinical characteristics and comorbidities in asthmatic and nonasthmatic patients with COVID-19. We also determined the risk of hospitalization associated with asthma and/or inhaled corticosteroid use.


      Medical records of patients with COVID-19 were searched by a computer algorithm (March 1 to April 15, 2020), and chart review was used to validate the diagnosis of asthma and medications prescribed for asthma. All patients had PCR-confirmed COVID-19. Demographic and clinical features were characterized. Regression models were used to assess the associations between asthma and corticosteroid use and the risk of COVID-19–related hospitalization.


      Of 1526 patients identified with COVID-19, 220 (14%) were classified as having asthma. Asthma was not associated with an increased risk of hospitalization (relative risk, 0.96; 95% CI, 0.77-1.19) after adjusting for age, sex, and comorbidities. The ongoing use of inhaled corticosteroids did not increase the risk of hospitalization in a similar adjusted model (relative risk, 1.39; 95% CI, 0.90-2.15).


      Despite a substantial prevalence of asthma in our COVID-19 cohort, asthma was not associated with an increased risk of hospitalization. Similarly, the use of inhaled corticosteroids with or without systemic corticosteroids was not associated with COVID-19–related hospitalization.

      Key words

      Abbreviations used:

      BMI (Body mass index), CAD (Coronary artery disease), CDC (Centers for Disease Control and Prevention), COPD (Chronic obstructive pulmonary disease), COVID-19 (Coronavirus disease 2019), DM (Diabetes mellitus), HTN (Hypertension), ICD-10 (International Classification of Diseases, Tenth Revision), ICS (Inhaled corticosteroid), ICU (Intensive care unit), LABA (Long-acting β-agonist), OSA (Obstructive sleep apnea), RR (Relative risk), SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2)
      To read this article in full you will need to make a payment


      Subscribe to Journal of Allergy and Clinical Immunology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • van Doremalen N.
        • Bushmaker T.
        • Morris D.H.
        • Holbrook M.G.
        • Gamble A.
        • Williamson B.N.
        • et al.
        Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1.
        N Engl J Med. 2020; 382: 1564-1567
        • Richardson S.
        • Hirsch J.S.
        • Narasimhan M.
        • Crawford J.M.
        • McGinn T.
        • Davidson K.W.
        • et al.
        Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area.
        JAMA. 2020; 323: 2052-2059
        • Arentz M.
        • Yim E.
        • Klaff L.
        • Lokhandwala S.
        • Riedo F.X.
        • Chong M.
        • et al.
        Characteristics and outcomes of 21 critically Ill patients with COVID-19 in Washington State.
        JAMA. 2020; 323: 1612-1614
        • Zhou Y.
        • Liu Y.
        Recent trends in current asthma prevalence among US adults, 2009-2018.
        J Allergy Clin Immunol Pract. 2020; (S2213-2198:30398-6)
        • NHIS, Centers for Disease Control and Prevention
        Most recent national asthma data.
        (Available at:) (Accessed May 6, 2020)
        • Sears M.R.
        Epidemiology of asthma exacerbations.
        J Allergy Clin Immunol. 2008; 122: 662-668
        • Wark P.A.
        • Tooze M.
        • Powell H.
        • Parsons K.
        Viral and bacterial infection in acute asthma and chronic obstructive pulmonary disease increases the risk of readmission.
        Respirology. 2013; 18: 996-1002
        • Ko F.W.
        • Chan P.K.
        • Chan R.W.Y.
        • Chan K.P.
        • Ip A.
        • Kwok A.
        • et al.
        Molecular detection of respiratory pathogens and typing of human rhinovirus of adults hospitalized for exacerbation of asthma and chronic obstructive pulmonary disease.
        Respir Res. 2019; 20: 210
        • Zheng X.Y.
        • Xu Y.J.
        • Guan W.J.
        • Lin L.F.
        Regional, age and respiratory-secretion-specific prevalence of respiratory viruses associated with asthma exacerbation: a literature review.
        Arch Virol. 2018; 163: 845-853
        • Chen N.
        • Zhou M.
        • Dong X.
        • Qu J.
        • Gong F.
        • Han Y.
        • et al.
        Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.
        Lancet. 2020; 395: 507-513
      1. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan [published online ahead of print April 12, 2020]. J Allergy Clin Immunol.

        • Bhatraju P.K.
        • Ghassemieh B.J.
        • Nichols M.
        • Kim R.
        • Jerome K.R.
        • Nalla A.K.
        • et al.
        Covid-19 in critically ill patients in the Seattle region—case series.
        N Engl J Med. 2020; 382: 2012-2022
        • Garg S.
        Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019—COVID-NET, 14 states, March 1–30, 2020.
        MMWR Morb Mortal Wkly Rep. 2020; 69
        • Myers L.C.
        • Parodi S.M.
        • Escobar G.J.
        • Liu V.X.
        Characteristics of hospitalized adults with COVID-19 in an integrated health care system in California.
        JAMA. 2020; 323: 2195-2198
        • Velavan T.P.
        • Meyer C.G.
        Mild versus severe COVID-19: laboratory markers.
        Int J Infect Dis. 2020; 95: 304-7
        • Chicago Department of Public Health, Chicago Health Atlas
        Asthma: adults who have been diagnosed with asthma.
        (Available at:)
        • Cazzola M.
        • Calzetta L.
        • Bettoncelli G.
        • Novelli L.
        • Cricelli C.
        • Rogliani P.
        Asthma and comorbid medical illness.
        Eur Respir J. 2011; 38: 42-49
        • ten Brinke A.
        • Sterk P.J.
        • Masclee A.A.
        • Spinhoven P.
        • Schmidt J.T.
        • Zwinderman A.H.
        • et al.
        Risk factors of frequent exacerbations in difficult-to-treat asthma.
        Eur Respir J. 2005; 26: 812-818
        • Hekking P.P.
        • Amelink M.
        • Wener R.R.
        • Bouvy M.L.
        • Bel E.H.
        Comorbidities in difficult-to-control asthma.
        J Allergy Clin Immunol Pract. 2018; 6: 108-113
        • Johnston S.L.
        Overview of virus-induced airway disease.
        Proc Am Thoracic Soc. 2005; 2: 150-156
        • Halpin D.M.G.
        • Faner R.
        • Sibila O.
        • Badia J.R.
        • Agusti A.
        Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection?.
        Lancet Respir Med. 2020; 8: 436-438
        • Halpin D.M.G.
        • Singh D.
        • Hadfield R.M.
        Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective.
        Eur Respir J. 2020; 552001009
        • Li W.
        • Moore M.J.
        • Vasilieva N.
        • Sui J.
        • Wong S.K.
        • Berne M.A.
        • et al.
        Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus.
        Nature. 2003; 426: 450-454
        • Zhou P.
        • Yang X.-L.
        • Wang X.-G.
        • Hu B.
        • Zhang L.
        • Zhang W.
        • et al.
        A pneumonia outbreak associated with a new coronavirus of probable bat origin.
        Nature. 2020; 579: 270-273
        • Hoffmann M.
        • Kleine-Weber H.
        • Schroeder S.
        • Krüger N.
        • Herrler T.
        • Erichsen S.
        • et al.
        SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor.
        Cell. 2020; 181: 271-280
      2. Jackson DJ, Busse WW, Bacharier LB, Kattan M, O’Connor GT, Wood RA, et al. Association of respiratory allergy, asthma and expression of the SARS-CoV-2 receptor, ACE2 [published online ahead of print April 22, 2020]. J Allergy Clin Immunol.

      3. Peters MC, Sajuthi S, Deford P, Christenson S, Rios CL, Montgomery MT, et al. COVID-19 related genes in sputum cells in asthma: relationship to demographic features and corticosteroids [published online ahead of print April 29, 2020]. Am J Respir Crit Care Med.

      4. Matsuyama S, Kawase M, Nao N, Shirato K, Ujike M, Kamitani W, et al. The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15 [published online ahead of print March 12, 2020]. bioRxiv.